NCT00681187

Somatuline Autogel Preference and Health Economy Study

A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Ipsen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary aim of this study is to assess which method of lanreotide Autogel administration patients with neuroendocrine tumours prefer - self/partner administrations or healthcare provided administrations. The study will also assess if self/partner administration can be performed without loss of efficacy and with a preserved safety profile. The impact of self/partner administration on resource utilisation and costs will be studied. In addition, we will also assess the healthcare provider's experience of the two administration practices.

Conditions

• Neuroendocrine Tumour With Carcinoid Symptoms

Interventions

Type	Name	Description
DRUG	lanreotide (Autogel formulation)	90 mg or 120 mg once every 28th day

Timeline

• Start date: 2008-06-01
• Primary completion: 2010-08-01
• Completion: 2010-08-01
• First posted: 2008-05-21
• Last updated: 2019-11-22
• Results posted: 2012-03-13

Locations

10 sites across 3 countries: Denmark, Norway, Sweden